Distributor inventory
Liraglutide 6 mg/mL solution for injection (prefilled pen 3 mL; total 18 mg)
Type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycaemic control); chronic weight management in adults with obesity/overweight with weight-related comorbidities (only if prescribed for this indication)
Liraglutide is a GLP-1 receptor agonist that increases glucose-dependent insulin secretion and reduces inappropriate glucagon release. It also slows gastric emptying and reduces appetite, helping lower blood glucose and support weight loss.
Subcutaneous injection once daily at the same time each day, independent of meals. Inject into abdomen, thigh, or upper arm; rotate sites and do not inject intravenously or intramuscularly. Typical titration: start 0.6 mg daily for 1 week, then 1.2 mg daily; may increase to 1.8 mg daily if needed (as directed by doctor). Use a new needle each time and follow pen instructions.
Common side effects of VICTOZA LIRAGLUTID PEN may include:
Not for type 1 diabetes or diabetic ketoacidosis. Risk of pancreatitis—seek urgent care for severe persistent abdominal pain (with/without vomiting). Contraindicated/avoid in patients with personal/family history of medullary thyroid carcinoma or MEN2; report neck lump/hoarseness/dysphagia. Use caution in severe GI disease (e.g., gastroparesis) and in renal impairment due to dehydration from GI side effects; monitor kidney function if significant vomiting/diarrhoea occurs. Monitor for gallbladder disease symptoms. Hypoglycaemia risk increases when used with insulin or sulfonylureas—dose adjustment may be needed. Do not share pens; use only with compatible needles.
